JP2023093527A5 - - Google Patents

Download PDF

Info

Publication number
JP2023093527A5
JP2023093527A5 JP2023060867A JP2023060867A JP2023093527A5 JP 2023093527 A5 JP2023093527 A5 JP 2023093527A5 JP 2023060867 A JP2023060867 A JP 2023060867A JP 2023060867 A JP2023060867 A JP 2023060867A JP 2023093527 A5 JP2023093527 A5 JP 2023093527A5
Authority
JP
Japan
Prior art keywords
fgfr2
days
once
leucovorin
oxaliplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023060867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023093527A (ja
JP7573062B2 (ja
Filing date
Publication date
Priority claimed from JP2019562617A external-priority patent/JP7299842B2/ja
Application filed filed Critical
Publication of JP2023093527A publication Critical patent/JP2023093527A/ja
Publication of JP2023093527A5 publication Critical patent/JP2023093527A5/ja
Priority to JP2024177680A priority Critical patent/JP2025004195A/ja
Application granted granted Critical
Publication of JP7573062B2 publication Critical patent/JP7573062B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023060867A 2017-05-16 2023-04-04 がん治療における化学療法剤と組み合わせた抗fgfr2抗体 Active JP7573062B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177680A JP2025004195A (ja) 2017-05-16 2024-10-10 がん治療における化学療法剤と組み合わせた抗fgfr2抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762507053P 2017-05-16 2017-05-16
US62/507,053 2017-05-16
US201762581992P 2017-11-06 2017-11-06
US62/581,992 2017-11-06
JP2019562617A JP7299842B2 (ja) 2017-05-16 2018-05-15 がん治療における化学療法剤と組み合わせた抗fgfr2抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019562617A Division JP7299842B2 (ja) 2017-05-16 2018-05-15 がん治療における化学療法剤と組み合わせた抗fgfr2抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177680A Division JP2025004195A (ja) 2017-05-16 2024-10-10 がん治療における化学療法剤と組み合わせた抗fgfr2抗体

Publications (3)

Publication Number Publication Date
JP2023093527A JP2023093527A (ja) 2023-07-04
JP2023093527A5 true JP2023093527A5 (cg-RX-API-DMAC7.html) 2024-01-04
JP7573062B2 JP7573062B2 (ja) 2024-10-24

Family

ID=62567776

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019562617A Active JP7299842B2 (ja) 2017-05-16 2018-05-15 がん治療における化学療法剤と組み合わせた抗fgfr2抗体
JP2023060867A Active JP7573062B2 (ja) 2017-05-16 2023-04-04 がん治療における化学療法剤と組み合わせた抗fgfr2抗体
JP2024177680A Pending JP2025004195A (ja) 2017-05-16 2024-10-10 がん治療における化学療法剤と組み合わせた抗fgfr2抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019562617A Active JP7299842B2 (ja) 2017-05-16 2018-05-15 がん治療における化学療法剤と組み合わせた抗fgfr2抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177680A Pending JP2025004195A (ja) 2017-05-16 2024-10-10 がん治療における化学療法剤と組み合わせた抗fgfr2抗体

Country Status (23)

Country Link
US (3) US11091555B2 (cg-RX-API-DMAC7.html)
EP (2) EP4650004A3 (cg-RX-API-DMAC7.html)
JP (3) JP7299842B2 (cg-RX-API-DMAC7.html)
KR (2) KR102749931B1 (cg-RX-API-DMAC7.html)
CN (2) CN110621336B (cg-RX-API-DMAC7.html)
AU (2) AU2018269984B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019023898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3062177A1 (cg-RX-API-DMAC7.html)
DK (1) DK3624837T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041987T3 (cg-RX-API-DMAC7.html)
FI (1) FI3624837T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251144T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073202T2 (cg-RX-API-DMAC7.html)
IL (1) IL270454B2 (cg-RX-API-DMAC7.html)
LT (1) LT3624837T (cg-RX-API-DMAC7.html)
MX (1) MX2024000614A (cg-RX-API-DMAC7.html)
PL (1) PL3624837T3 (cg-RX-API-DMAC7.html)
PT (1) PT3624837T (cg-RX-API-DMAC7.html)
RS (1) RS67296B1 (cg-RX-API-DMAC7.html)
SG (1) SG10202112636SA (cg-RX-API-DMAC7.html)
SI (1) SI3624837T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500362T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018213304A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
CN114846029A (zh) * 2019-12-24 2022-08-02 迪哲(江苏)医药股份有限公司 新颖抗fgfr2b抗体
CN111760026B (zh) * 2020-08-06 2026-04-03 汪炬 FGFR2b抑制分子在制备治疗PAF介导的疾病药物中的应用
EP4273166A4 (en) * 2020-12-29 2025-04-16 Shenzhen Forward Pharmaceuticals Co., Limited ANTI-FGFR2 ANTIBODIES AND USE THEREOF
TW202342527A (zh) * 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
KR20250126131A (ko) * 2022-12-28 2025-08-22 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 항-fgfr2b 항체 및 이의 용도
EP4786494A1 (en) 2023-09-28 2026-08-05 Nanjing Leads Biolabs Co., Ltd. Anti-fgfr2 antibody and multispecific binding molecule comprising same
TW202540177A (zh) * 2023-11-14 2025-10-16 大陸商蘇州創勝醫藥集團有限公司 抗-FGFR2b免疫偶聯物及其於治療癌症的用途
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
CN120424212A (zh) * 2024-01-26 2025-08-05 上海安领科生物医药有限公司 抗FGFR2b抗体及抗体药物偶联物
CN117925825B (zh) * 2024-01-31 2024-09-13 中国医学科学院北京协和医院 包含ncoa7的标志物组合在诊断圆锥角膜中的应用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997048813A2 (en) 1996-06-18 1997-12-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fibroblast growth factor receptor activating gene 1 (frag1). fgfr2-frag1 fusions
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトkgfrに対する抗体
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ES2363765T3 (es) 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistas de fgfr.
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
KR100493460B1 (ko) 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 fgfr2 이성체
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
SI1680140T1 (sl) 2003-10-16 2011-08-31 Imclone Llc Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
US8945572B2 (en) 2006-05-12 2015-02-03 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
CA2655246A1 (en) 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP2094733A1 (en) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
WO2008079849A2 (en) 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2676529C (en) 2007-01-24 2014-03-25 Kyowa Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
WO2008118877A2 (en) 2007-03-23 2008-10-02 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
CA2682382A1 (en) 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
WO2012021841A2 (en) 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2009151448A1 (en) 2008-06-10 2009-12-17 University Of Southern California Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury
AU2010313621C1 (en) 2009-10-14 2015-11-26 Humanigen, Inc. Antibodies to EphA3
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US9140689B2 (en) 2010-03-14 2015-09-22 Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
CA2800311A1 (en) 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
MX2014007121A (es) 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
CA2868791A1 (en) 2012-03-30 2013-10-03 The Regents Of The University Of California Anti-emp2 therapy reduces cancer stem cells
AU2013247645B2 (en) 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2014007369A1 (ja) 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Fgfr2融合遺伝子
WO2014089193A1 (en) 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CA2908391A1 (en) 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer
CN105658810B (zh) 2013-06-13 2020-08-21 南澳大学 用于检测前列腺癌的方法
MX374785B (es) * 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
US20170175197A1 (en) 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling

Similar Documents

Publication Publication Date Title
JP2025004195A5 (cg-RX-API-DMAC7.html)
FI3624837T3 (fi) Anti-fgfr2-vasta-aineita yhdistelmässä kemoterapia-aineiden kanssa syövän hoidossa
CN108601831B (zh) 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
JP2023511595A5 (cg-RX-API-DMAC7.html)
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2018521976A5 (cg-RX-API-DMAC7.html)
JP2019517549A5 (cg-RX-API-DMAC7.html)
D’Haens et al. Advances in biologic therapy for ulcerative colitis and Crohn’s disease
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
JP2023501375A5 (cg-RX-API-DMAC7.html)
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
JP2014500278A5 (cg-RX-API-DMAC7.html)
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2021514003A5 (cg-RX-API-DMAC7.html)
WO2025103379A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
JP2022501332A5 (cg-RX-API-DMAC7.html)
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
JP2021511344A5 (cg-RX-API-DMAC7.html)
US20120020989A1 (en) Methods of treating colorectal cancer
JP2020521798A5 (cg-RX-API-DMAC7.html)
CN112043832A (zh) 用于联合治疗胃癌的喹啉类化合物
JP2024514087A5 (cg-RX-API-DMAC7.html)
JP2023500480A5 (cg-RX-API-DMAC7.html)
EP3733202A1 (en) Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer
EP4514391A1 (en) Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor